{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:44:16Z","timestamp":1775526256773,"version":"3.50.1"},"reference-count":26,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/13543784.2023.2263362","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:25:30Z","timestamp":1696328730000},"page":"849-853","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents"],"prefix":"10.1080","volume":"32","author":[{"given":"Adel","family":"Hajj Ali","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandini","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-9797","authenticated-orcid":false,"given":"Milind Y","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16358-7"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc3701.095952"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910401"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01381-3"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.11.021"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.027"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3456"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062534"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024656"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.020"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01290"},{"key":"e_1_3_4_17_1","unstructured":"MyoKardia IawosoB-MS. Full prescribing information: Camzyos. FDA medication Guide MyoKardia Inc. A wholly owned subsidiary of Bristol-Myers Squibb 2022. p. 1\u201327."},{"key":"e_1_3_4_18_1","unstructured":"PM BJ. In: StatPearls [internet]. [Updated 2023 Jan 17] (Treasure Island (FL): StatPearls Publishing; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582152\/)."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6120118"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318346"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(21)01891-X"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs150"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00021.2020"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02190-7"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02176-5"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02184-5"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02190-7"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2263362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:32:57Z","timestamp":1708000377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2263362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/13543784.2023.2263362"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2263362","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}